Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data NovaBridge Biosciences files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
4.31
236
13.8
-1.55
0.63
Cost of revenue
7.29
3.95
Gross profit
6.53
-5.5
Research and development
121
151
190
22.5
21.4
21.8
62.9
General and administrative
94
61.7
141
29
28.2
29.7
31.4
Operating expenses
51.5
72.6
51.4
94.3
Operating income
-53.1
-72
-51.4
-94.3
Interest expense
0.43
0.15
0
0
0.1
Interest income
4.39
3.71
3.35
4.95
9.29
7.49
7.61
Other non-operating income
-2.9
63.3
13.1
-28.3
-8.09
-4.72
-1.68
Pre-tax income
-209
74
-366
-141
-82.2
-49.7
-88.3
Income tax
1.87
-0.5
0.1
0
0
0
Income from continuing operations
-210
23.8
-325
-141
-82.2
-49.7
-46.3
Net income to minority interests
-42.1
Net income
-209
72.2
-366
-371
-208
-22.2
-46.3
EBITDA
-52.9
-71.5
-51.1
-94.2
EPS, basic
-28.90
0.54
-2.09
-1.96
-1.09
-0.12
-0.21
EPS, diluted
-28.90
0.46
-2.09
-1.96
-1.09
-0.12
-0.21
Shares, basic (weighted)
7.38
134
175
190
191
187
220
Shares, diluted (weighted)
7.38
157
175
190
191
187
220
Balance sheet
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
163
729
553
343
292
68.3
211
Short-term investments
4.6
4.83
118
34.1
20.2
105
0.21
Receivables
20
5.19
0
Inventory
4.27
0
Other current assets
19.5
30
29.9
11.6
2.5
3.3
6.68
Total current assets
196
819
750
526
330
177
218
Property, plant and equipment
4.32
3.87
7.17
8.82
1.78
0.2
0.14
Lease right-of-use assets
2.36
2.3
17.7
9.15
3.78
3.6
2.81
Goodwill
23.4
24.9
25.5
23.6
Intangible assets
21.4
18.5
18.8
17.2
16.6
Long-term investments
30.8
0
Other non-current assets
2.63
0.31
4.18
1.58
0.25
1.37
2.81
Total assets
250
971
879
591
369
213
261
Accounts payable
39.3
85.9
93.1
102
7.85
7.53
16.8
Accrued liabilities
4.33
14.4
8.24
6.3
2.4
2.63
2.78
Deferred revenue
1.26
0.31
Short-term debt
7.18
2.75
4.22
Total current liabilities
84.5
88.3
97.9
110
58.1
8.45
26.9
Lease liabilities
1.08
0.85
12.8
4.65
3.26
3.07
2.18
Other non-current liabilities
1.38
2.34
2.46
0.11
0
0.51
Total liabilities
96
108
163
169
126
11.5
29.6
Paid-in capital
55.9
1,180
1,428
1,389
1,475
1,460
1,527
Retained earnings
-358
-310
-683
-995
-1,264
-1,286
-1,332
Treasury stock
-3.08
-8.01
-6.23
-5.04
Other comprehensive income
10.1
-7.78
-29.3
31
39.8
33.4
41.5
Shareholders' equity
-292
862
715
418
243
201
231
Total equity
-292
862
715
418
243
201
231
Total liabilities and equity
250
971
879
591
369
213
261
Shares outstanding
8.36
165
184
191
186
187
265
Cash flow statement
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-209
72.2
-366
-371
-208
-22.2
-88.3
Depreciation and amortization
1.41
1.95
2.16
0.2
0.5
0.3
0.07
Stock-based compensation
52.7
75.6
95.5
13.1
10.2
-1.95
5.97
Change in receivables
-20
15.3
-2.76
Change in inventory
-4.27
3.95
Change in payables
27.1
26.6
23.9
18.3
-35.7
-0.21
18.1
Cash from operations
-125
66.4
-153
-160
-184
-52.7
-20.6
Capital expenditures
-1.76
-1.23
-4.7
-2.09
-0.16
-0.05
-0.01
Purchases of investments
-19.2
-382
-1,596
-1,074
-125
-51.1
-50
Sales and maturities of investments
764
85
110
155
Cash from investing
30.5
-30.9
-114
66.5
14.4
-136
105
Stock issued
1.42
8.05
6.92
0.41
0.2
Share buybacks
-5.34
0
-3.01
-8.64
-0.34
Cash from financing
21.9
527
93.2
6.14
1.07
-0.34
57.7
Exchange rate effect
2.18
-16.3
-20.2
Net change in cash
-70
546
-194
-77.3
-165
-242
142
Free cash flow
-126
65.2
-157
-162
-184
-52.7
-20.6
Interest paid
0.43
0.15
0.1
Income taxes paid
0.1
0
0
0
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $1.38 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-21.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-19.6%
Net income / average total assets.
Return on invested capital (ROIC)
-97.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
14.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-17.9%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-23.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
22.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-23.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-23.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
18.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
5.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
7.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
8.09x
Current assets / current liabilities.
Quick ratio
7.84x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
7.84x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.21
Net income per basic share, as reported (split-adjusted).
FCF per share
-$0.09
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.09
Cash from operations / diluted weighted shares.
Book value per share
$0.87
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.69x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.69x
Market cap / tangible book value, when positive.
FCF yield
-12.9%
Free cash flow / market cap.
Earnings yield
-29.1%
Net income / market cap (the inverse of P/E).
Was NovaBridge Biosciences profitable in fiscal 2025?
No. It reported a net loss of $46.3M.
How much free cash flow did NovaBridge Biosciences generate in fiscal 2025?
Cash from operations of $20.6M minus capital expenditures of $7.0K left free cash flow of -$20.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.